Anti-Ro/SSA antibodies are associated with severe mitral valve regurgitation in patients with systemic lupus erythematosus

作者：Higuera Ortiz Violeta; Mora Arias Tania; Castillo Martinez Diana; Amezcua Guerra Luis M^*

来源：Modern Rheumatology, 2017, 27(3): 476-480.

DOI：10.1080/14397595.2016.1208136

• Anti-Ro
• SSA antibodies
• Mitral valve regurgitation
• Systemic lupus erythematosus

Objective: To assess whether anti-Ro/SSA antibodies are associated with cardiac valve disease in lupus.Methods: A single-center, medical chart review was performed. Lupus patients were divided according to its anti-Ro/SSA status and subgroups were compared for valvular abnormalities and other characteristics. Dependence of anti-Ro/SSA reactivity to anti-Ro52/TRIM21 antibodies was also evaluated.Results: Eighty-nine lupus patients were analyzed. The most common valvular abnormalities were tricuspid (60%), mitral (41%) and pulmonary (14%) regurgitation. Thirty-six patients were positive and 53 negative for anti-Ro/SSA antibodies. In patients positive to anti-Ro/SSA, a difference was noted for anti-dsDNA (67 versus 45%; p=0.04) and anti-La/SSB (19 versus 2%; p=0.004) antibodies. An association between anti-Ro/SSA antibodies and severe mitral regurgitation was observed; indeed, 4/15 patients with anti-Ro/SSA and mitral regurgitation had severe forms of valvulopathy as compared to only 1/22 patients with mitral regurgitation but negative to such antibody (27 versus 5%; p=0.02). Anti-Ro/SSA antibodies significantly elevated the risk of severe mitral regurgitation (OR=5). Anti-Ro52/TRIM21 levels (10329 versus 42 +/- 43U/mL; p=0.03) and anti-Ro52/TRIM21:anti-Ro/SSA ratios (0.88 +/- 0.02versus 0.35 +/- 0.37; p=0.03) were higher in patients with mitral valve regurgitation than in those with no valvulopathy.Conclusion: Anti-Ro/SSA antibodies, mainly against Ro52/TRIM21 antigens, may be pathologically involved in lupus-associated mitral valve regurgitation.

• 出版日期2017